Boehringer Ingelheim Acquires Vira Therapeutics Stakes for Development of Immuno- Oncology Viral Therapies
Shots:
- The total acquisition value is based on option and share agreement i.e. EUR 210M signed in 2016 b/w two companies. Under the deal ViraTherapeutics will operate in Innsbruck- Austria as a unit of BI’s Discovery Research organization
- The focus of this deal is to develop innovative viral-based oncology treatments for transforming the lives of cancer patients and improving their QoL
- Vira is a combination of two investors EMBL Ventures and the BIVF. BIVF has EUR 250M under management and supervises unit of 22 active companies
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
